Why the study?
Newer anticancer therapies such as tyrosine kinase inhibitors, angiogenesis inhibitors, and checkpoint inhibitors are associated with significant adverse cardiovascular effects alongside established cardiotoxic agents.
What are the mechanisms, imaging modalities for early identification, and prevention strategies for cardiotoxicity associated with cancer therapies?
What are the mechanisms, imaging modalities for early identification, and prevention strategies for cardiotoxicity associated with cancer therapies?
This review highlights the critical need for early identification and management of cardiotoxicity associated with a wide range of cancer therapies to prevent cardiac morbidity and mortality.
Answers are grounded in this paper and cite their sources.
Supports multimodality imaging surveillance in cancer patients; leaves open optimal prevention strategies pending prospective trials.
Cardiotoxicity is a known complication of many cancer therapies. While the cardiotoxicity of established agents such as anthracyclines, antimetabolites, and alkylating agents is well known, it is important to realize that newer anticancer therapies such as tyrosine kinase inhibitors, angiogenesis inhibitors, and checkpoint inhibitors are also associated with significant adverse cardiovascular effects. Echocardiography, magnetic resonance imaging, and radionuclide imaging have been used to identify these complications early and prevent further consequences. We will discuss the different classes of cancer therapeutic agents that cause cardiotoxicity, the mechanisms that lead to these effects, and strategies that can be used to prevent the cardiac morbidity and mortality associated with their use.
No takes yet. Share an insight, caveat, or question.
Mondal et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: